The breakthrough, described in a study published in Cell, could help overcome some of the biggest obstacles facing cancer immunotherapy, including the difficulty of manufacturing enough immune cells and keeping them active in the body. In experiments involving mice, the engineered cells established themselves in bone marrow, produced new immune cells, and slowed the progression of both blood cancers and solid tumors.